Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Anika Therapeutics stock (ANIK)

Buy Anika Therapeutics stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Anika Therapeutics is a medical instruments & supplies business based in the US. Anika Therapeutics shares (ANIK) are listed on the NASDAQ and all prices are listed in US Dollars. Anika Therapeutics employs 357 staff and has a trailing 12-month revenue of around $169.3 million.

Our top picks for where to buy Anika Therapeutics stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for transfer bonus

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for Investing by theme

Go to site
Earn up to $300 on new deposits
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

How to buy Anika Therapeutics stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – ANIK. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Anika Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 6 of 6
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Finder Score: 4.4 / 5: ★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
Stocks, Options, Mutual funds, ETFs, Alternatives
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
Finder Score: 3.1 / 5: ★★★★★
Stocks, ETFs
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
Cash App
Finder Score: 3 / 5: ★★★★★
Cash App
Stocks, ETFs, Cryptocurrency
Buy and sell over 1,800 stocks and ETFs commission-free and for as little as $1.
Finder Score: 4.3 / 5: ★★★★★
Stocks, Options, ETFs
Up to 8.10%
Get up to 15 free stocks
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Finder Score: 4.2 / 5: ★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Anika Therapeutics stock price (NASDAQ: ANIK)

Use our graph to track the performance of ANIK stocks over time.

Anika Therapeutics shares at a glance

Information last updated 2024-07-14.
Latest market close$28.06
52-week range$16.54 - $28.67
50-day moving average $26.05
200-day moving average $23.62
Wall St. target price$31.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-5.24

Is it a good time to buy Anika Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Anika Therapeutics price performance over time

Historical closes compared with the close of $28.06 from 2024-07-18

1 week (2024-07-12) 3.43%
1 month (2024-06-20) 8.01%
3 months (2024-04-19) 8.59%
6 months (2024-01-19) 26.17%
1 year (2023-07-20) 10.26%
2 years (2022-07-20) 24.32%
3 years (2021-07-20) 40.32
5 years (2019-07-19) 40.62

Is Anika Therapeutics stock undervalued or overvalued?

Valuing Anika Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Anika Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Anika Therapeutics's PEG ratio

Anika Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.2321. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Anika Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Anika Therapeutics's EBITDA

Anika Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4 million.

The EBITDA is a measure of a Anika Therapeutics's overall financial performance and is widely used to measure a its profitability.

Anika Therapeutics financials

Revenue TTM $169.3 million
Gross profit TTM $96.8 million
Return on assets TTM -1.81%
Return on equity TTM -31.61%
Profit margin -45.39%
Book value $14.07
Market Capitalization $395.8 million

TTM: trailing 12 months

Anika Therapeutics share dividends

We're not expecting Anika Therapeutics to pay a dividend over the next 12 months.

Anika Therapeutics share price volatility

Over the last 12 months, Anika Therapeutics's shares have ranged in value from as little as $16.54 up to $28.6691. A popular way to gauge a stock's volatility is its "beta".

ANIK.US volatility(beta: 0.83)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Anika Therapeutics's is 0.827. This would suggest that Anika Therapeutics's shares are less volatile than average (for this exchange).

Anika Therapeutics overview

Anika Therapeutics, Inc. , a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Frequently asked questions

What percentage of Anika Therapeutics is owned by insiders or institutions?
Currently 3.051% of Anika Therapeutics shares are held by insiders and 91.351% by institutions.
How many people work for Anika Therapeutics?
Latest data suggests 357 work at Anika Therapeutics.
When does the fiscal year end for Anika Therapeutics?
Anika Therapeutics's fiscal year ends in December.
Where is Anika Therapeutics based?
Anika Therapeutics's address is: 32 Wiggins Avenue, Bedford, MA, United States, 01730
What is Anika Therapeutics's ISIN number?
Anika Therapeutics's international securities identification number is: US0352551081
What is Anika Therapeutics's CUSIP number?
Anika Therapeutics's Committee on Uniform Securities Identification Procedures number is: 035255108

More guides on Finder

Ask a question provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site